Artelo reports ART27.13 pain study results

• Artelo Biosciences reported nonclinical results showing ART27.13 reduced neuropathic pain behaviors in an animal model.
• The cannabinoid receptor agonist decreased mechanical allodynia and thermal hyperalgesia after repeated dosing.
• Artelo said the findings support further evaluation of ART27.13 in oncology supportive care.

Artelo Biosciences (NASDAQ:ARTL) reported new nonclinical data showing ART27.13 reduced neuropathic pain-associated behaviors in a paclitaxel-induced peripheral neuropathy model in male and female animals.

The results add to ongoing research on ART27.13, which is currently being evaluated in the Phase 2 CAReS study for cancer-related anorexia cachexia syndrome (CACS).

In the nonclinical study, repeated dosing with ART27.13 decreased mechanical allodynia and thermal hyperalgesia, two measures commonly used to evaluate pain responses in preclinical models.

Artelo said interim CAReS Phase 2 results previously showed positive trends in body weight, lean body mass and activity levels, with a favorable safety profile at doses up to 1,300 micrograms per day.

ART27.13 is a peripherally restricted dual cannabinoid receptor agonist designed to activate cannabinoid pathways while limiting activity in the central nervous system.

Artelo continues developing ART27.13 for CACS, a condition associated with weight loss and muscle loss in cancer patients that currently has no FDA-approved treatments.